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Abstract: Complexes of the diuretic benzothiadiazine derivative chlorothiazide (6-chloro-7-sulfamoyl-
1,2,4-benzothiadiazine-l,l-dioxide) with V(IV); Fe(II); Co(II); Ni(II); Cu(II), Ag(I) and U(VI) were
prepared and characterized by elemental analysis, spectroscopic, thermogravimetric, magnetic and
conductimetric measurements. The complexes behave as effective inhibitors for two isozymes (I and II) of
carbonic anhydrase (CA).
Introduction
Benzothiadiazines constitute an important class of pharmacological agents-’3 with wide
applications in clinical medicine as diuretics, antihypertensive drugs as well as hyperglycemic agents
among others. 3’4 Originally developed as inhibitors of the enzyme carbonic anhydrase (CA, EC 4.2.1.1),
these compounds exhibited different pharmacological properties, such as increased elimination of salt in
urine, which ultimately led to the development of saluretic drugs such as chlorothiazide,
hydrochlorothiazide, cyclothiazide, etc.
--5 as well as to the high-ceiling diuretics of the furosemide type.
In previous papers’6 we investigated the coordination chemistry of diazoxide 16 and chlorothiazide
21 as well as the biological activity (as enzyme inhibitors) of the prepared metal complexes. It was proved
that transition metal ions such as Cu(II); Zn(II); Hg(II) or Co(II) among others lead to coordination
compounds with greatly increased CA inhibitory properties as compared to the original sulfonamides.
Moreover, the complexes of chlorothiazide 2 were more effective as compared to those of diazoxide 1. As
only the chlorothiazide complexes of Zn(II); Cd(II); Hg(II) and of some main group cations were reported,
in this paper we extend the study to some other biologically relevant cations.
Cl
Me
2
1: HDZO
H2NO2S
2
2: HCTZ
The present paper describes the preparation of complexes of the conjugated base of 2 with V(IV);
Fe(III); Co(II); Ni(II); Cu(II); Ag(I) and U(VI), their characterization as well as biological activity data for
the inhibition of two CA isozymes (erythrocyte CA and II enzymes, which are the predominant and mostly
investigated cytoplasmic CAsS’7).
Materials and Methods
IR spectra were obtained in KBr pellets, with a Perkin Elmer 1600 instrument, in the range 200
4000 cm1. Electronic spectra were obtained by the diffuse reflectance technique in MgO as reference, with
a Perkin Elmer Lambda 17 apparatus. Solution electronic spectra were recorded in acetonitrile with a Cary
3 instrument. Conductimetric measurements were done in DMF solutions, at 25C (concentrations of mM
of complex) with a Fisher conductimeter. Magnetic susceptibility measurements were done at room
temperature by Faraday’s method, using CoHg(NCS)4 as standard. Elemental analyses were done by
combustion for C,H,N with an automated Carlo Erba analyzer, and gravimetrically for the metal ions, and
79Vol. 3, No. 2, 1996 Coordination Compounds ofChlorothiazide
were + 0.4% of the theoretical values. Thermogravimetric measurements were done in air, at a heating rate
of 10C/rain., with a Perkin Elmer 3600 thermobalance.
Chlorothiazide, metal salts (vanadyl sulfate; iron(III) perchlorate; M(II) nitrates, where M Co,
Ni, Cu; silver(I) nitrate and uranyl nitrate) and solvents were from Aldrich or Merck and were fised without
further purification. Human isozymes CA and II, buffers and 4-nitrophenyl acetate were from Sigma.
Inhibitors were assayed spectrophotometrically at 400 nm, by the method of Pocker and Stone for the
inhibition of 4-nitrophenyl acetate hydrolysis catalyzed by the two CA isozymes.
Synthesis of coordination compounds 4-10
A cold solution of chlorothiazide sodium salt (NaCTZ, 3) was prepared by suspending HCTZ in the
stoichiometric amount of 2N NaOH solution, working at 0-5C. Mention should be made that the
benzothiadiazinic ring is not very stable in the presence of bases, being cleaved to orthanilamide
derivatives.
9 Still, at room temperature and in 2N NaOH, this ring is cleaved in about 150 hours,
9 so that,
presumably, no decomposition occurred during the experiments reported here, in which complexes were
prepared in about 0.5 hours. The cold solution obtained above, was mixed with a methanolic-aqueous
solution of metal salts in molar ratios of 2:l(for the divalent cations, the vanadyl and uranyl salts); 1:1 (for
Ag(I)) or 3:1 (for Fe(III)). The obtained reaction mixture was stirred magnetically at room temperature for
0.5 hours. The complexes so obtained were collected by filtration and air-dried. Due to their poor
solubility in the majority of solvents (excepting for DMSO and DMF) recrystallization attempts of the new
complexes were unsuccessful.
Results and Discussion
The chlorothiazide complexes 4-10 prepared in the present work together with their elemental
analysis (within + 0.4% of the theoretical values calculated for the proposed formulas) and TG data are
shown in Table I.
Table I: The prepared chlorothiazide complexes 4-10, their elemental analysis and TG data (CTZ stands for
the endocyclic SOzNH deprotonated species of chlorothiazide).
No. Compound Analysis (calc./found)
%M
a %C
b %H
b %N
b %H20
4 [VO(CTZ)2(OH2)2I
5 [Fe(CTZ)3(OH2)3]
6 [Co(CTZ)2(OH2)4I
7 [Ni(CTZ)2(OH2)4]]
8 [Cu(CTZ)2(OH2)4]
9 [Ag(CTZ)(OH2)]
7.0/6.8
5.3/5.3
7.8/7.9
7.8/7.6
8.4/8.3
24.8/25.0
10 [UO2(CTZ)2(OH2)3] 25.3/25.5
26.6/26.8
27.8/27 7
25.6/25.6
25.7/25 5
25.5/25 2
22.1/22 2
20.4/20
2.5/2.4 11.6/11.5 5.0/5.24
2.6/2.3 12.1/12.0 5.2/5.0
2.9/2.6 11.2/11.4 9.6/9.5
2.9/3.0 11.2/11.0 9.6/9.7
2.9/2.5 11.1/11.1 9.5/9.3
2.0/1.8 9.6/9.4 4.1/3.8g
2.1/2.1 8.9/8.5 5.7/5.5
aBy gravimetry; bBy combustion; By TG analysis;
4 Corresponding to 2.H20, lost between 150-175C;
Corresponding to 3 H20, lost between 150-180C; Corresponding to 4 H20, lost between 140-180C;
Corresponding to 1 H20, lost between 160-185C.
The new complexes were also characterized by spectroscopic, magnetic and conductimetric data
(Tables II and III).
In the IR spectra of complexes 4-10, the only major changes as compared to the spectrum of 2,
concern the sulfonamido vibrations, in the region 1100-1400 cm-1. As shown in the previous paper, due to
the fact that chlorothiazide has two types of sulfonamido moieties (the endo- and the exocyclic ones), two
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bands appear for both the symmetrical as well as antisymmetrical SO2 vibrations (Table II). As in the
previously reported complexes, only the band corresponding to the endocyclic SO2 group undergoes shifts
towards lower wavenumbers (with 27-35 cm-
for the symmetrical vibrations, and 20-36 cm, for the
antisymmetrical ones, respectively) in complexes 4-10, proving the participation of the endocyclic SO2N
moiety in interaction with the metal ions, as well as the fact that the 7-substituent, the SO2NHz moiety is not
involved in complexation. Another difference in the IR spectra of the complexes consists in the presence of
vibrations under 400 cm, tentatively assigned as due to M-N and M-O vibrations.
,7 One reaches the same
conclusion regarding the donor atom of chlorothiazide in its complexes reported here, by comparing
solution electronic spectra of 2, its sodium salt 3 and complexes 4-10. In the last compounds as well as in
the sodium salt, only one broad band appears at 323 nm, whereas in 2 two absorption maxima were
evidenced. This type of modification of electronic spectrum in the presence of bases or by formation of
complexes was previously documented for related systems (heterocyclic sulfonamides
,7,1o or for the related
benzothiadiazine derivative, hydrochlorothiazide). Thus, in all these complexes, as in those previously
reported, the chlorothiazidate anion behaves as a monodentate ligand, interacting with the metal ions
through the N-2 atom.
Table II" IR and solution electronic spectral data for compounds 2-10.
Comp. Color IR, Spectra
a ,cm. UV Spectra
b
v(M-L) v(SO2)s v(SO2)as ’max, nm (lge)
2 1117, 1180 1325, 1377 278 (3.82); 328 (2.13)
3 1121, 1185 1345 323 (4.18)
4 gray 345;398 1085, 1180 1300, 1375 323 (4.20)
5 brown 340;398 1086, 1180 1302, 1377 322 (4.73)
6 pink 350;400 1090, 1180 1300, 1377 323 (4.19)
7 green 348;400 1087, 1180 1300, 1376 323 (4.25)
8 emerald 350;400 1087, 1179 1303, 1375 323 (4.22)
9 white 337;396 1082, 1180 1305, 1377 323 (3.98)
10 yellow 330;398 1084, 1179 1289, 1377 323 (4.27)
a In KBr;
b In acetonitrile.
Supplementary information regarding the stereochemistry of metal ions in the prepared complexes
was obtained by means of diffuse reflectance electronic spectroscopy as well magnetic moment
measurements (Table III).
Table III: Diffuse reflectance spectra, magnetic moments and proposed geometries for complexes 4-10.
Complex Electronic spectra (v, cml)
a
l,eff (BM)
b Geometry
4 25,900; 15,500; l,900(sh) 1.85 square pyramidal
5 24,650; 20,300; 10,500 5.75 octahedral
6 25,600; 18,700(sh); 15,600 5.25 octahedral
7 17,000; 12,500 3.46 octahedral
8 16,200 1.90 octahedral
9 c d linear
10 23,400, 21,600 0.67 pentagonal bipyramidal
a In MgO as standard material;
d Diamagnetic.
b At room temperature;
c No transitions in this spectral region seen;
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From the above data, it is seen that the V(IV) derivative 4 is in its predilect geometry square
pyramidal,
12 similarly with the related diazoxide complex previously reported,
6 whereas the iron derivative
5 in octahedral geometry (electronic spectrum and magnetic moment typical for this geometry of Fe(III)13).
In these derivatives the water molecules, coordinated to the metal ions as proved by TG data (Table I)
complete the coordination sphere around the metal, in addition to the two and three, respectively,
chlorothiazidate ligands.
The other metal ions showing an interesting RD spectrum in their complexes with chlorothiazide
are Co(II) in 6, Ni(II) in 7 and Cu(II) in $. Two bands were detected in the RD spectrum of 6, situated at
25,600 and 15,600 cm
1 respectively, assigned as the v3 and v2 transitions, as well as a shoulder at 18,700
-1 cm The V calculated from the Lever tables is 7,260 ,which leads to a v2/vl ratio in the range of 2.1-2.2,
which, correlated with a magnetic moment of 5.25 BM at room temperature, suggests an octahedral
geometry for the Co(II) ion.
14 This is also supported by TG analysis data (Table I), which proved that the
four water molecules coordinated to the metal ion are lost in a single step, between 140-180 C. For the
-1 Ni(II) complex 7, two weak transitions were evidenced in the RD spectrum, at 17,000 and 12,500 cm
attributed to the V and v2 transitions of Ni(II) in octahedral surrounding. 5’6 This is also supported by the
magnetic moment of 3.46 BM.6’15 The Cu(II) complex $ shows a large structureless band centered at
16,200 cm
1 and a magnetic moment of 1.90 BM, indicating probably a distorted octahedral geometry of
Cu(II).6’16 In the last two complexes water is also directly bound to the metal ions, since by means of TG
analysis it was shown that this is lost in one step, between 140-180C. The Ag(I) derivative 9 probably
possesses a linear geometry with the chlorothiazidate and water ligands occupying the two coordination
sites of silver.
17 Finally, the electronic spectrum and the rest of analytical data of the uranyl derivative 10
are consistent with heptacoordinated U(VI), similarly to other such derivatives previously reported by us.s
Conductilnetric measurements (data not shown) proved all complexes 4-10 to be of the non-electrolyte type,
in contrast to the sodium salt 3 which behaved as an 1’1 electrolyte. All these data are consistent with the
structures proposed above for the new complexes of chlorothiazide.
Inhibition data against the major red cell CA isozymes (CA I and CA II) with the new complexes
are shown in Table IV.
Table IV CA I and II inhibition data for 4-nitrophenyl acetate hydrolysis reaction, in the presence of
compounds 1-10.
Inhibitor IC5o (ktM)
a
CA CA II
1 (HDZO) 115 58
2 (HCTZ) 104 20
4 62 14
5 50 13
6 37 10
7 44 8
$ 6 1.2
9 14 2.4
10 13 1.5
a Molarity of inhibitor producing a 50% decrease of enzyme specific activity for the esterasic activity of
these enzymes.
As seen from the above data, all the new complexes are stronger inhibitors, towards both isozymes,
as compared to chlorothiazide or the related benzothiadiazine, diazoxide. Cations leading to very effective
inhibitors were Cu(II); Ag(I) and U(VI). In fact, all these three cations were previously reported to form
complexes with aromatic/heterocyclic sulfonamides showing 100-1000 times better inhibition profiles, as
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compared to the parent ligands. 7"1’13 Although in previous papers we explained this phenomenon as due to
binding of the cations contained in the complex inhibitors to residue His-64 in CA II active site, it seems
that supplementary binding sites are available at the entrance of CA II active site, as we
9 recently
discovered a histidine cluster in that region, formed from residues 3, 4, 10, 15, 17 and 64. This would
explain the higher affinity of coordination compounds to this isozyme, as well as the catalytic properties of
the respective isozyme per se. In principle, by using this approach for the design of novel CA inhibitors, it
would be possible to obtain compounds with specificity towards certain isozymes and their selective
inhibition. This would eventually allow us to understand the physiological function for some of the eight
CA isozymes, as presently this seem to be certain only for CA II and CA IV.
References
1. C.T.Supuran, Main Group Met. (.7hem., in press.
2. F.C.Novello and J.M.Sprague, J.Am. Chem.Soc., 1957, 79, 2028-2029.
3. a) K.H.Beyer and J.E.Baer, Pharmacol.Rev., 1961, 13, 517-562; b) I.M.Weiner, in "The Pharmacological
Basis of Therapeutics", 8th Edition, A.G.Gilman, T.W.RaI1, A.S.Nies and P.Taylor Eds., Pergamon Press,
New York, 1990, pp. 713-732.
4. a) M.B.Standen, J.M.Quayle, N.W.Davies, J.E.Brayden, Y.Huang and M.T.Nelson, Science, 1989, 245,
177-180; b) J.G.Gerben and A.S.Nies, in "The Pharmacological Basis of Therapeutics", 8th Edition,
A.G.Gihnan, T.W.RalI, A.S.Nies and P.Taylor Eds., Pergamon Press, New York, 1990, pp. 784-813; c)
S.R.Levin, M.A.Charles, M.O’Connor and G.M.Grodsky, Am.J.Physiol.,1975, 299, 49-54; d) C.R.Kahn and
Y.Schechter, in "The Pharmacological Basis of Therapeutics", 8th Edition, A.G.Gilman, T.W.RalI,
A.S.Nies and P.Taylor Eds., Pergamon Press, New York, 1990, pp. 1463-1495.
5. T.H.Maren, Pharmacol.Rev., 1967, 47, 595-782.
6. C.T.Supuran, Metal Based Drugs, 1995, 2, 327-330.
7. C.T.Supuran, in "Carbonic Anhydrase and Modulation of Physiologic and Pathologic Processes in the
Organism", I.Puscas Ed., Helicon, Timisoara 1994, pp. 29-111.
8. Y.Pocker and J.T.Stone, Biochemistry, 1967, 6, 668-679.
9. a) J.H.Freeman and E.C.Wagner, J.Org.Chem., 1951, 16, 815-837; b) F.C.Novello, S.C.Bell,
E.L.A.Abrams, C.Ziegler and J.M.Sprague, J.Org.Chem., 1960, 25, 970-981; c)J.K.Wales, S.V.Krees,
A.M.Grant, J.K.Viktora and F.W.Wolff, J.Pharmacol.Exp.Ther., 1968, 164, 421-431.
10. G.Alzuet, S.Ferrer, J.Borras and C.T.Supuran, Roum.C,hem.Quart.Rev., 1994, 2, 283-300.
11. H.Abdine, M.A.Elsayed and Y.M.Elsayed, J.Assoc. OffAnal. (_7hem., 1978, 61,695-701.
12. C.J.Balhausen and H.Gray, lnorg.Chem., 1962, 1, 111-115.
13. C.T.Supuran, Rev. Roum.Chim., 1992, 37, 849-855.
14. L.Banci, A.Bencini, C.Benelli, D.Gatteschi and C.Zanchini, Struct.Bonding, 1982, 52, 37-79.
15. B.N.Figgis, "Introduction to Ligand Field Theory", J.Wiley &Sons, New York, 1966.
16. G. Alzuet, J.Casanova, J.Borras, J.A.Ramirez and O.Carugo, J.lnorg.Biochem., 1995, 57, 219-234
17. A.Bult, in "Metal Ions in Biological Systems", H.Sigel Ed., Vol. 16,, M.Dekker, New York, 1983, pp.
261-278
18. C.T.Supuran, Rev.Roum. Chim., 1993, 38, 229-236.
19. I.Bertini, F.Briganti, A.Scozzafava and C.T.Supuran, manuscript in preparation.
Received" January 15, 1996 Accepted" February 26, 1996
Received in revised camera-ready format" March 11, 1996
83